FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection

Virology Journal

Volumn 6, Issue , 2009, Pages

  Rose, William A ^a   McGowin, Chris L ^b   Pyles, Richard B ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FSL 1 PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; DIACYLGLYCEROL; FSL 1 LIPOPROTEIN, SYNTHETIC; FSL-1 LIPOPROTEIN, SYNTHETIC; OLIGOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM; CELL CULTURE; COMPREHENSION; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG ACTIVITY; ENVIRONMENT; EPITHELIUM CELL; FEMALE; GENITAL TRACT INFECTION; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; INFECTION RESISTANCE; INNATE IMMUNITY; KINETICS; MOUSE; NONHUMAN; ORGAN WEIGHT; OUTCOME ASSESSMENT; TIME; VAGINA EPITHELIUM; VAGINA MUCOSA; VAGINAL LAVAGE; VIRUS TRANSMISSION; ANIMAL; DISEASE MODEL; DRUG POTENTIATION; GENITAL HERPES; IMMUNOLOGY; INTRAVAGINAL DRUG ADMINISTRATION; VIRUS REPLICATION;

BACTERIA (MICROORGANISMS); HUMAN HERPESVIRUS 2; MUS;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; BACTERIAL PROTEINS; CELLS, CULTURED; CYTOKINES; DIGLYCERIDES; DISEASE MODELS, ANIMAL; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; IMMUNITY, INNATE; MICE; OLIGOPEPTIDES; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 6; VIRUS REPLICATION;

EID: 72749113793     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-6-195     Document Type: Article

References (49)

1. Genital herpes. R Gupta T Warren A Wald, Lancet 2007 370 2127 37 10.1016/S0140-6736(07)61908-4 18156035
2. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. AJ Nahmias FK Lee S Beckman-Nahmias, Scand J Infect Dis Suppl 1990 69 19 36 2175939
3. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. F Xu MR Sternberg BJ Kottiri GM McQuillan FK Lee AJ Nahmias SM Berman LE Markowitz, Jama 2006 296 964 73 10.1001/jama.296.8.964 16926356
4. Herpes simplex virus type 2 (HSV-2) establishes latent infection in a different population of ganglionic neurons than HSV-1: role of latency-associated transcripts. TP Margolis Y Imai L Yang V Vallas PR Krause, J Virol 2007 81 1872 8 17151134 10.1128/JVI.02110-06 (Pubitemid 46214459)
5. Viral sexually transmitted infections and bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. JE Allsworth VA Lewis JF Peipert, Sex Transm Dis 2008 35 791 6 10.1097/OLQ.0b013e3181788301 18607314
6. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. EE Freeman HA Weiss JR Glynn PL Cross JA Whitworth RJ Hayes, Aids 2006 20 73 83 10.1097/01.aids.0000198081.09337.a7 16327322
7. Prevalent herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptibility to multiple sexually transmitted infections. R Kaul NJ Nagelkerke J Kimani E Ngugi JJ Bwayo KS Macdonald A Rebbaprgada K Fonck M Temmerman AR Ronald S Moses, J Infect Dis 2007 196 1692 7 10.1086/522006 18008255
8. Genital herpes: review of the epidemic and potential use of type-specific serology. RL Ashley A Wald, Clin Microbiol Rev 1999 12 1 8 9880471
9. Herpes simplex: insights on pathogenesis and possible vaccines. DM Koelle L Corey, Annu Rev Med 2008 59 381 95 10.1146/annurev.med.59.061606.095540 18186706
10. Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group. KH Fife CS Crumpacker GJ Mertz EL Hill GS Boone, J Infect Dis 1994 169 1338 41 8195614
11. Pathogen recognition and inflammatory signaling in innate immune defenses. TH Mogensen, Clin Microbiol Rev 2009 22 240 73 10.1128/CMR.00046-08 19366914
12. Innate immunity to virus infection. O Takeuchi S Akira, Immunol Rev 2009 227 75 86 10.1111/j.1600-065X.2008.00737.x 19120477
13. Quantification and comparison of toll-like receptor expression and responsiveness in primary and immortalized human female lower genital tract epithelia. MM Herbst-Kralovetz AJ Quayle M Ficarra S Greene WA Rose R Chesson RA Spagnuolo RB Pyles, Am J Reprod Immunol 2008 59 212 24 10.1111/j.1600-0897. 2007.00566.x 18201283
14. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. AA Ashkar XD Yao N Gill D Sajic AJ Patrick KL Rosenthal, J Infect Dis 2004 190 1841 9 10.1086/425079 15499542
15. Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production. N Gill PM Deacon B Lichty KL Mossman AA Ashkar, J Virol 2006 80 9943 50 17005672 10.1128/JVI.01036-06 (Pubitemid 44522588)
16. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. AM Harandi K Eriksson J Holmgren, J Virol 2003 77 953 62 12502811 10.1128/JVI.77.2.953-962. 2003 (Pubitemid 36055517)
17. Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection. MM Herbst-Kralovetz RB Pyles, J Virol 2006 80 9988 97 17005677 10.1128/JVI.01099-06 (Pubitemid 44522593)
18. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. RB Pyles D Higgins C Chalk A Zalar J Eiden C Brown G Van Nest LR Stanberry, J Virol 2002 76 11387 96 12388699 10.1128/JVI.76.22.11387-11396.2002 (Pubitemid 35231294)
19. Role of IFN-alpha/beta signaling in the prevention of genital herpes virus type 2 infection. A Svensson L Bellner M Magnusson K Eriksson, J Reprod Immunol 2007 74 114 23 10.1016/j.jri.2006.09.002 17092567
20. FimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling. AA Ashkar KL Mossman BK Coombes CL Gyles R Mackenzie, PLoS Pathog 2008 4 1000233 19057665 10.1371/journal.ppat.1000233
21. Signaling pathways induced by lipoproteins derived from Mycoplasma salivarium and a synthetic lipopeptide (FSL-1) in normal human gingival fibroblasts. J Nakamura K Shibata A Hasebe T Into T Watanabe N Ohata, Microbiol Immunol 2002 46 151 8 12008923
22. Relationship between structures and biological activities of mycoplasmal diacylated lipopeptides and their recognition by toll-like receptors 2 and 6. T Okusawa M Fujita J Nakamura T Into M Yasuda A Yoshimura Y Hara A Hasebe DT Golenbock M Morita Y Kuroki T Ogawa K Shibata, Infect Immun 2004 72 1657 65 14977973 10.1128/IAI.72.3.1657-1665.2004 (Pubitemid 38263789)
23. Effect of toll-like receptor (TLR) agonists on TLR and microbicide expression in uterine and vaginal tissues of the mouse. G Soboll TM Schaefer CR Wira, Am J Reprod Immunol 2006 55 434 46 10.1111/j.1600-0897.2006.00381.x 16674601
24. Toll-like receptors, innate immunity and HSV pathogenesis. M Herbst-Kralovetz R Pyles, Herpes 2006 13 37 41 16895653
25. The diacylated lipopeptide FSL-1 enhances phagocytosis of bacteria by macrophages through a Toll-like receptor 2-mediated signalling pathway. M Mae M Iyori M Yasuda HM Shamsul H Kataoka K Kiura A Hasebe Y Totsuka K Shibata, FEMS Immunol Med Microbiol 2007 49 398 409 10.1111/j.1574-695X.2007.00218.x 17316370
26. Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract. GN Milligan DI Bernstein, Virology 1995 206 234 41 10.1016/S0042-6822(95)80038-7 7831778
27. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2). WA Rose C Tuthill RB Pyles, Int J Antimicrob Agents 2008 32 262 6 10.1016/j.ijantimicag.2008.04.010 18619817
28. Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay. L Corey ML Huang S Selke A Wald, J Med Virol 2005 76 350 5 10.1002/jmv.20365 15902702
29. Vaginal microbicides: where are we and where are we going? AB Moscicki, J Infect Chemother 2008 14 337 41 10.1007/s10156-008-0630-3 18936885
30. Guiding the vaginal microbicide trials with biomarkers of inflammation. RN Fichorova, J Acquir Immune Defic Syndr 2004 37 Suppl 3 184 93 16419271
31. HSV shedding. SL Sacks PD Griffiths L Corey C Cohen A Cunningham GM Dusheiko S Self S Spruance LR Stanberry A Wald RJ Whitley, Antiviral Res 2004 63 Suppl 1 19 26 10.1016/j.antiviral.2004.06.004 15450382
32. HSV-2 transmission. SL Sacks PD Griffiths L Corey C Cohen A Cunningham GM Dusheiko S Self S Spruance LR Stanberry A Wald RJ Whitley, Antiviral Res 2004 63 Suppl 1 27 35 10.1016/j.antiviral.2004.06.005 15450383
33. Predicting the potential individual- and population-level effects of imperfect herpes simplex virus type 2 vaccines. EJ Schwartz S Blower, J Infect Dis 2005 191 1734 46 10.1086/429299 15838802
34. Role of mucosal immunity in preventing genital herpes infection. V MasCasullo E Fam MJ Keller BC Herold, Viral Immunol 2005 18 595 606 10.1089/vim.2005.18.595 16359226
35. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Lund A Sato S Akira R Medzhitov A Iwasaki, J Exp Med 2003 198 513 20 12900525 10.1084/jem.20030162 (Pubitemid 36976063)
36. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. L Alexopoulou AC Holt R Medzhitov RA Flavell, Nature 2001 413 732 8 10.1038/35099560 11607032
37. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. F Heil H Hemmi H Hochrein F Ampenberger C Kirschning S Akira G Lipford H Wagner S Bauer, Science 2004 303 1526 9 10.1126/science.1093620 14976262
38. A polymer-type water-soluble peptidoglycan exhibited both Toll-like receptor 2- and NOD2-agonistic activities, resulting in synergistic activation of human monocytic cells. M Natsuka A Uehara S Yang S Echigo H Takada, Innate Immun 2008 14 298 308 10.1177/1753425908096518 18809654
39. Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. LH Travassos SE Girardin DJ Philpott D Blanot MA Nahori C Werts IG Boneca, EMBO Rep 2004 5 1000 6 15359270 10.1038/sj.embor. 7400248 (Pubitemid 39534459)
40. Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity. AM Harandi B Svennerholm J Holmgren K Eriksson, J Virol 2001 75 6705 9 11413339 10.1128/JVI.75.14.6705-6709.2001 (Pubitemid 32578191)
41. Protective vaccination against genital herpes simplex virus type 2 (HSV-2) infection in mice is associated with a rapid induction of local IFN-gamma-dependent RANTES production following a vaginal viral challenge. AM Harandi B Svennerholm J Holmgren K Eriksson, Am J Reprod Immunol 2001 46 420 4 10.1034/j.1600-0897.2001.d01-34.x 11775012
42. Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. GN Milligan DI Bernstein, Virology 1997 229 259 68 10.1006/viro.1997.8441 9123869
43. Novel antiviral activity of chemokines. T Nakayama J Shirane K Hieshima M Shibano M Watanabe Z Jin D Nagakubo T Saito Y Shimomura O Yoshie, Virology 2006 350 484 92 10.1016/j.virol.2006.03.004 16603217
44. The role of gamma interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice. MB Parr EL Parr, Virology 1999 258 282 94 10.1006/viro.1999.9739 10366565
45. Acute genital infection in guinea pigs: effect of recombinant interleukin-2 on herpes simplex virus type 2. A Weinberg L Rasmussen TC Merigan, J Infect Dis 1986 154 134 40 3011918
46. Antiviral actions of interferons. CE Samuel, Clin Microbiol Rev 2001 14 778 809 11585785 10.1128/CMR.14.4.778-809.2001 (Pubitemid 32979631)
47. Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. AM Harandi B Svennerholm J Holmgren K Eriksson, J Gen Virol 2001 82 845 53 11257190
48. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. A Lahiri P Das D Chakravortty, Vaccine 2008 26 6777 83 10.1016/j.vaccine.2008.09.045 18835576
49. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. X Zhang AA Chentoufi G Dasgupta AB Nesburn M Wu X Zhu D Carpenter SL Wechsler S You L BenMohamed, Mucosal Immunol 2009 2 129 43 10.1038/mi.2008.81 19129756